JP2023511434A5 - - Google Patents
Info
- Publication number
- JP2023511434A5 JP2023511434A5 JP2022544734A JP2022544734A JP2023511434A5 JP 2023511434 A5 JP2023511434 A5 JP 2023511434A5 JP 2022544734 A JP2022544734 A JP 2022544734A JP 2022544734 A JP2022544734 A JP 2022544734A JP 2023511434 A5 JP2023511434 A5 JP 2023511434A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- nucleotide
- dsrna agent
- chain
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965452P | 2020-01-24 | 2020-01-24 | |
| US62/965,452 | 2020-01-24 | ||
| US202163138717P | 2021-01-18 | 2021-01-18 | |
| US63/138,717 | 2021-01-18 | ||
| PCT/US2021/014729 WO2021150969A1 (en) | 2020-01-24 | 2021-01-22 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511434A JP2023511434A (ja) | 2023-03-17 |
| JP2023511434A5 true JP2023511434A5 (https=) | 2024-01-30 |
| JP7826211B2 JP7826211B2 (ja) | 2026-03-09 |
Family
ID=76992618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544734A Active JP7826211B2 (ja) | 2020-01-24 | 2021-01-22 | ロイシンリッチリピートキナーゼ２（ＬＲＲＫ２）ｉＲＮＡ剤組成物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230126233A1 (https=) |
| EP (1) | EP4093872A4 (https=) |
| JP (1) | JP7826211B2 (https=) |
| KR (1) | KR20220133246A (https=) |
| CN (1) | CN115298312A (https=) |
| AU (1) | AU2021211723A1 (https=) |
| BR (1) | BR112022014590A2 (https=) |
| CA (1) | CA3168871A1 (https=) |
| IL (1) | IL294728A (https=) |
| MX (1) | MX2022009026A (https=) |
| TW (1) | TW202142690A (https=) |
| WO (1) | WO2021150969A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4731763A1 (en) * | 2023-06-20 | 2026-04-29 | Adarx Pharmaceuticals, Inc. | Lrrk2-modulating compositions and methods of use thereof |
| AU2024353921A1 (en) * | 2023-09-27 | 2026-04-16 | Neuro3 Therapeutics (Suzhou) Ltd. | Novel sirna constructs, therapeutics, and modifications |
| CN120082552A (zh) * | 2023-12-01 | 2025-06-03 | 艾码生物科技(南京)有限公司 | 初级-miRNA及其应用 |
| TW202600826A (zh) * | 2024-03-14 | 2026-01-01 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ＬＲＲＫ２的ＲＮＡｉ劑及其醫藥用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124096A2 (en) * | 2006-04-21 | 2007-11-01 | The Trustees Of Columbia University In The City Of New York | Lrrk2 regulaton of neuronal process morphology |
| WO2008091799A2 (en) * | 2007-01-22 | 2008-07-31 | The Trustees Of Columbia University In The City Of New York | Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants |
| GB201004475D0 (en) * | 2010-03-17 | 2010-05-05 | Isis Innovation | Gene silencing |
| EA038792B1 (ru) * | 2013-05-22 | 2021-10-20 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2017087282A1 (en) * | 2015-11-18 | 2017-05-26 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
-
2021
- 2021-01-22 AU AU2021211723A patent/AU2021211723A1/en active Pending
- 2021-01-22 MX MX2022009026A patent/MX2022009026A/es unknown
- 2021-01-22 IL IL294728A patent/IL294728A/en unknown
- 2021-01-22 CN CN202180021227.2A patent/CN115298312A/zh active Pending
- 2021-01-22 US US17/794,637 patent/US20230126233A1/en active Pending
- 2021-01-22 JP JP2022544734A patent/JP7826211B2/ja active Active
- 2021-01-22 BR BR112022014590A patent/BR112022014590A2/pt unknown
- 2021-01-22 CA CA3168871A patent/CA3168871A1/en active Pending
- 2021-01-22 WO PCT/US2021/014729 patent/WO2021150969A1/en not_active Ceased
- 2021-01-22 KR KR1020227029378A patent/KR20220133246A/ko active Pending
- 2021-01-22 EP EP21744004.9A patent/EP4093872A4/en active Pending
- 2021-01-25 TW TW110102736A patent/TW202142690A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7805386B2 (ja) | Ｌｐａ発現を阻害するための組成物及び方法 | |
| JP2023511434A5 (https=) | ||
| JP2022515193A5 (https=) | ||
| TWI727963B (zh) | 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關疾病之使用方法 | |
| JP2023521604A5 (https=) | ||
| JP7830319B2 (ja) | ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法 | |
| JP2023523993A5 (https=) | ||
| TW201831685A (zh) | 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法 | |
| CN115397436B (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| JP2022501057A5 (https=) | ||
| CN108186667A (zh) | RNAi试剂、组合物及其用于治疗甲状腺素运载蛋白（TTR）相关疾病的使用方法 | |
| CN114761557B (zh) | 具有最小氟含量的小干扰rna的化学修饰 | |
| JP2024536811A5 (https=) | ||
| IL294728A (en) | lrrk2 RNA material preparations and methods of using them | |
| JP2023018065A (ja) | Ｒｅｖｅｒｓｉｒ（商標）化合物 | |
| JP2023544413A5 (https=) | ||
| JP2024528503A5 (https=) | ||
| TW202229551A (zh) | 用於治療或預防ＳＮＣＡ相關的神經退化性疾病的ＳＮＣＡ ｉＲＮＡ組成物及其使用方法 | |
| US20240401059A1 (en) | Compositions and methods for modulating pnpla3 expression | |
| JP7560616B2 (ja) | 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法 | |
| JP2024522068A5 (https=) | ||
| JP2024509783A5 (https=) | ||
| TW202305134A (zh) | 杭丁頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法 | |
| TW202328447A (zh) | 用於降低dmpk表現之化合物與方法 | |
| JP2025507372A5 (https=) |